The Rare Gene Variant Behind Families Who Age Without the Inflammation
A note from Dr. Goel
This week I want to show you something different — not a compound, not a peptide, but a single change in a single gene that appears to buy some families over a decade of extra healthy life. It's one of the clearest human demonstrations yet that chronic inflammation, not just genetics in general, is a real lever on how fast we age.
Researchers behind the Leiden Longevity Study just published new findings on exactly this, and I think it reframes how we should talk about "longevity genes." Let's get into it.
— Dr. Sanjeev Goel
This week's deep dive: the gene that lets some families age without the inflammation
Most longevity-gene hunting compares random long-lived people to random short-lived people and hopes something falls out of the statistical noise. A new analysis from the Leiden Longevity Study took a cleaner approach — and it landed on a mutation in a gene most of us have never heard of: CGAS.
What makes it different
Instead of scanning unrelated centenarians, the Leiden team studied 212 sibships — groups of siblings, all long-lived, from the same two parents. That family-based design lets researchers zero in on genomic regions actually shared by long-lived relatives, then test what those variants do in the lab, rather than just noting a correlation. That step — from statistical hit to mechanism — is what makes this one worth your attention.
What the research shows
Leiden Longevity Study
An affected sib-pair analysis of 212 long-lived sibships identified four genomic regions linked to familial longevity and prioritized 12 rare protein-altering variants across seven genes, including CGAS.
The CGAS variant (rs200818241)
Found in two of the long-lived sibships, this missense mutation reduced cGAS protein stability and blunted activation of the cGAS-STING pathway in human and mouse cell models — the same pathway implicated in the chronic, low-grade inflammation researchers call “inflammaging.”
Presented at ESHG 2026 (Gothenburg, June)
In the broader Leiden cohort, middle-aged offspring of long-lived parents developed cardiometabolic disease an average of 13 years later than their same-age spouses whose own parents were shorter-lived — a within-family comparison designed to control for shared lifestyle and environment.
The honest caveats
Two sibships carrying one rare variant is a small signal — this is hypothesis-generating, not proof that CGAS alone drives human longevity. It's also a rare, largely non-modifiable germline mutation: there is no supplement, peptide, or protocol today that reliably recreates "one working copy of CGAS." The 13-year cardiometabolic finding is an observational, within-family comparison, not a clinical trial. And as of this writing, the core findings live in a bioRxiv preprint and an ESHG conference presentation rather than a finalized paper in a top-tier journal — worth watching for independent replication before it hardens into consensus.
My take
This is the kind of longevity research I want more of — not a single gene sold as a silver bullet, but a mechanism (dialing down cGAS-STING signaling) that connects directly to something we can actually act on: chronic inflammatory burden. Most of us don't carry this rare variant, and no product on the market replicates it. But the same inflammaging pathway it targets is measurable, and to a real degree modifiable, through the basics — sleep, training load, body composition, and therapies specifically aimed at lowering inflammatory and senescence markers. That's the honest through-line here, not a shortcut.
If you're curious where your own inflammatory and biological-age markers stand, that's a conversation worth having with your physician — you can also see how we think about it at Peak Human.
Longevity news worth your minute
Rapamycin's longest human safety trial reports full-year results. The PEARL trial (48 weeks, 114 participants) found low-dose intermittent rapamycin was well tolerated and improved lean mass by about 5% in women, with modest shifts in biomarkers of biological aging.
Plasma exchange shows a measurable biological-age effect. A Buck Institute / Circulate Health randomized trial (Aging Cell, May 2025) found therapeutic plasma exchange combined with IVIG lowered biological age by an average of 2.6 years across 36 epigenetic clocks.
Attitude tracks with healthspan. A 2026 Yale School of Public Health study following nearly 4,000 adults over three years found 45% of participants aged 65+ improved in at least one domain of aging — about 32% cognitively and 28% physically — with gains more common among those holding more positive attitudes about aging.
Important disclaimer
This newsletter is for educational purposes only and is not medical advice. Compounds discussed may be investigational and not FDA-approved. Nothing here is a recommendation to start, stop, or change any treatment. Peptide and metabolic therapies carry real risks and should only be used under qualified medical supervision. Always consult your physician before making health decisions.